Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 8/20 | 0.57 |
| ▸ | QDPR | P09417 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1129031 | 0.98 | SLC18A3 (0.59) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| Iodide SCHEMBL16799291 | 0.98 | SLC18A3 (0.59) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL25788737 | 0.89 | SLC18A3 (0.50) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| Alcohol SCHEMBL27595503 | 0.89 | SLC18A3 (0.50) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL12640684 | 0.87 | HTR3A (0.66) | SLC18A3SIGMAR1HTR2CHTR3A | |
| SCHEMBL1002475 | 0.87 | HTR3A (0.66) | SLC18A3SIGMAR1HTR2CHTR3A | |
| Hydrochloric Acid SCHEMBL15300834 | 0.85 | HTR3A (0.63) | SLC18A3SIGMAR1HTR2CHTR3A | |
| Pyrrolidine SCHEMBL9026279 | 0.84 | CYP2D6 (0.45) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| Pivalate SCHEMBL25318872 | 0.83 | SIGMAR1 (0.49) | SLC18A3SIGMAR1HTR2CQDPRP2RY14 | |
| SCHEMBL265495 | 0.83 | KDM1A (0.48) | HTR2CMAPTSMN1; SMN2TDP1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768826-B | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2025-05-27 | — | — | CN | claimed |
| CN-119841766-A | Preparation method and application of glutarimide compound | 上海凌凯科技股份有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-116768826-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2023-09-19 | — | — | CN | claimed |
| CN-110590738-B | Synthetic method of 3, 6-dimethyl-1-secondary amino-7-cyano-8-hydroxyisoquinoline compound | 温州大学 | 2022-03-01 | — | — | CN | claimed |
| CN-110590738-A | Synthetic method of 3, 6-dimethyl-1-secondary amino-7-cyano-8-hydroxyisoquinoline compound | 温州大学 | 2019-12-20 | — | — | CN | claimed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| US-12552801-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4647431-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Gan & lee Pharm Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-6355642-B1 | PSYCHOLOGICAL DISORDERS AND BRAIN DISORDERS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6303593-B1 | FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-10-16 | — | — | US | disclosed |
| WO-2000051608-A1 | 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0937715-A1 | TETRAHYDROBENZINDOLE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1999-08-25 | — | — | EP | disclosed |
| US-5489599-A | FUNGICIDES | SHELL RESEARCH LIMITED (GB) | 1996-02-06 | — | — | US | disclosed |
| WO-1992012130-A1 | PIPERIDINE DERIVATIVES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494717-A1 | Piperidine derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | SLC18A3 4755/4885SIGMAR1 47/4885HTR2C 751/4885 |
| US-12552801-B2 | Indazole derivatives | EGFR, ABL1, ERBB3 | SLC18A3 2158/4885SIGMAR1 183/4885HTR2C 327/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | SLC18A3 4340/4885SIGMAR1 1435/4885HTR2C 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.